EGFR and lung cancer: This study, where mortality was observed in more than half the patients analyzed, could not replicate the results of the FLAURA study (1), which could have provided a rationale for selecting osimertinib as first-line therapy for patients aged ≥75 years with EGFR mutation-positive, nonsmall cell lung cancer.